Skip to content
Triangle logo TriangleGet started
← Study library

NCT01810588 · REGISTRY CONDITION SEARCH

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2026-08-19

In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes. We hypothesize that identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective recipient) is more important to the outcome of haplo cord transplant than the nucleated cell dose. The identification of such a graft for a large proportion of the subjects may necessitate accepting a lower umbilical cord graft dose. In addition to a umbilical cord blood transplant, recipients will receive stem cells from a family member ( a haplo-identical donor) . After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device. The subject will undergo a chemotherapy conditioning regimen prior to transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Subjects Who Achieved Engraftment With De-Escalating Umbilical Cord Total Nucleated Cell (TNC) Dose

→

outcome · NOT POSTED

Long-term Survival of Subjects Undergoing Haplo-cord Transplants

→

outcome · NOT POSTED

Impact of IPA Targeting on Transplant Outcome

→

outcome · NOT POSTED

Impact of NIMA Matching on Transplant Outcome

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Subject must have a confirmed diagnosis of: 1. Previously Relapsed or refractory acute leukemia (myeloid or lymphoid) 2. Acute leukemia in first remission at high-risk for recurrence 3. Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis 4. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma 5. Chronic lymphocytic leukemia, relapsed or with poor prognostic features 6. Multiple myeloma 7. Myelodysplastic syndrome 8. Chronic myeloproliferative disease 9. Hemoglobinopathies 10. Aplastic anemia 11. Other hematological disorder in need of allogeneic transplant (e.g. blastoid dendritic cell neoplasm) * Age ≥ 18 years * Likely to benefit from allogeneic transplant in the opinion of the transplant physician * An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame. * Karnofsky (KPS) Performance status of \>= 70% * Acceptable organ function as defined below: Serum bilirubin: \< 2.0mg/dL ALT(SGPT): \< 3 X upper limit of normal Creatinine Clearance: \> 50 mL/min/1.73m2 (as estimated by the modified MDRD equation) * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Life expectancy is severely limited by concomitant illness or uncontrolled infection * Severely decreased Left Ventricular Ejection Fraction (LVEF) or impaired pulmonary function tests (PFT's) * Evidence of chronic active hepatitis or cirrhosis * Uncontrolled HIV disease * Pregnant or lactating
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    All subjects in this cohort will receive a minimal cell dose of 2 x 10\^7 total nucleated cells (TNC)/kilogram (kg) for the umbilical cord blood unit. Haplo-cord transplantation: All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past. For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products. In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device.
    intervention Names
    1. Device: CliniMACS® CD34 Reagent System
    2. Drug: Fludarabine
    3. Drug: Melphalan
    4. Drug: anti-thymocyte globulin (rabbit)
    5. Drug: Rituximab
    6. Radiation: Total Body Irradiation
    7. Drug: Mycophenolate Mofetil
    8. Drug: Tacrolimus
    label
    Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    type
    EXPERIMENTAL
  2. description
    All subjects in this cohort will receive a minimal cell dose of 1 x 10\^7 total nucleated cells (TNC)/kilogram (kg) for the umbilical cord blood unit. Haplo-cord transplantation: All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past. For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products. In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device.
    intervention Names
    1. Device: CliniMACS® CD34 Reagent System
    2. Drug: Fludarabine
    3. Drug: Melphalan
    4. Drug: anti-thymocyte globulin (rabbit)
    5. Drug: Rituximab
    6. Radiation: Total Body Irradiation
    7. Drug: Mycophenolate Mofetil
    8. Drug: Tacrolimus
    label
    Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    type
    EXPERIMENTAL
  3. description
    All subjects in this cohort will receive a minimal cell dose of 0.5 x 10\^7 total nucleated cells (TNC)/kilogram (kg) for the umbilical cord blood unit. Haplo-cord transplantation: All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past. For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products. In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device.
    intervention Names
    1. Device: CliniMACS® CD34 Reagent System
    2. Drug: Fludarabine
    3. Drug: Melphalan
    4. Drug: anti-thymocyte globulin (rabbit)
    5. Drug: Rituximab
    6. Radiation: Total Body Irradiation
    7. Drug: Mycophenolate Mofetil
    8. Drug: Tacrolimus
    label
    Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    type
    EXPERIMENTAL
  4. description
    All subjects in this cohort will receive the minimum required cell dose that is determined following the dose de-escalation portion of the study (cohorts 1 through 3) Haplo-cord transplantation: All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past. For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products. In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device.
    intervention Names
    1. Device: CliniMACS® CD34 Reagent System
    2. Drug: Fludarabine
    3. Drug: Melphalan
    4. Drug: anti-thymocyte globulin (rabbit)
    5. Drug: Rituximab
    6. Radiation: Total Body Irradiation
    7. Drug: Mycophenolate Mofetil
    8. Drug: Tacrolimus
    label
    Cohort 4
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
    name
    CliniMACS® CD34 Reagent System
    type
    DEVICE
  2. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
    name
    Fludarabine
    other Names
    1. Fludara, Fludarabine phosphate
    type
    DRUG
  3. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
    name
    Melphalan
    type
    DRUG
  4. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
    name
    anti-thymocyte globulin (rabbit)
    other Names
    1. rATG, Rabbit ATG
    type
    DRUG
  5. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
    name
    Rituximab
    other Names
    1. Rituxan
    type
    DRUG
  6. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
    name
    Total Body Irradiation
    other Names
    1. TBI
    type
    RADIATION
  7. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
    name
    Mycophenolate Mofetil
    other Names
    1. Cellcept, MMF
    type
    DRUG
  8. arm Group Labels
    1. Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg
    2. Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg
    3. Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg
    4. Cohort 4
    description
    Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
    name
    Tacrolimus
    other Names
    1. Prograf
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
270
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    We aim to identify the lowest threshold of umbilical cord total nucleated cell (TNC) dose that can be utilized assure durable umbilical cord blood engraftment in the haplo-cord transplants. The threshold will be defined as the lowest dose which assures cord blood engraftment occurs in at least 80% of subjects.
    measure
    Number of Subjects Who Achieved Engraftment With De-Escalating Umbilical Cord Total Nucleated Cell (TNC) Dose
    time Frame
    100 days
secondary Outcomes
  1. description
    Evaluate the long term outcome of subjects undergoing haplo cord transplants using an optimally matched umbilical cord blood (UCB) graft (i.e. Survival, profession-free survival (PFS), Relapse, transplant-related mortality (TRM), toxicities, infections and GVHD)
    measure
    Long-term Survival of Subjects Undergoing Haplo-cord Transplants
    time Frame
    5 years after transplant
  2. description
    As much as possible, UCB units will be chosen to be IPA targeted. This is not always possible. We will therefore also retrospectively analyze transplant outcomes and correlate with IPA status.
    measure
    Impact of IPA Targeting on Transplant Outcome
    time Frame
    5 years from transplantation
  3. description
    As much as possible, UCB units will be chosen to be NIMA matched. This is not always possible. We will therefore also retrospectively analyze transplant outcomes and correlate with NIMA status.
    measure
    Impact of NIMA Matching on Transplant Outcome
    time Frame
    5 years from transplantation
Full study description
brief Summary
In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes. We hypothesize that identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective recipient) is more important to the outcome of haplo cord transplant than the nucleated cell dose. The identification of such a graft for a large proportion of the subjects may necessitate accepting a lower umbilical cord graft dose. In addition to a umbilical cord blood transplant, recipients will receive stem cells from a family member ( a haplo-identical donor) . After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device. The subject will undergo a chemotherapy conditioning regimen prior to transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.
detailed Description
This is a clinical trial for subjects with hematologic malignancies ( acute leukemia, myeloproliferative disorders, lymphoma, myeloma) who are in need of a donor stem cell transplant, and for whom an umbilical cord blood transplant is thought to be the best option. As donors for allogeneic transplant, we typically try to use related family members, such as brothers or sisters, or volunteer donors who are 'HLA matched', i.e. share similar proteins on their cells. This study is for subjects for whom such a matched sibling donor or a matched unrelated donor is not available. For such subjects a commonly used transplant procedure is to use stem cells from one or two umbilical cords (UCB) from a newborn. These umbilical cord blood grafts, despite not completely matching the recipient, cause few problems with graft vs host disease (a common complication of transplant). But they tend to grow very slowly and subjects often have very prolonged hospital stays and are at high risk for complications due to low blood counts. Umbilical cord blood transplant will be the standard arm for this protocol. This study uses a new method of bone marrow transplantation called combined haplo-identical cord (haplo-cord) transplantation. In this procedure, cells from a related donor who shares half of the HLA proteins ( haplo-identical) are collected from the blood, as well as cells from an umbilical cord, and then both are transplanted. It is hoped that by using cells from a haplo-identical relative, subjects will have a faster recovery and require fewer transfusions. Over time the haplo-identical cells from the relative are replaced by the cells from the cord blood. The combined transplantation of haplo-identical stem cells and cord blood has previously been used in approximately 60 subjects with very encouraging results. Traditionally it has been felt that the most important determinant of outcome of an UCB stem cell transplant is the cord blood cell dose. The second determinant is the degree of matching between donor and recipient. Many times, we have difficulty identifying UCB units of sufficient cell dose that are well matched. Of interest,in our prior study of haplo-cord SCT indicated outcomes seemed independent of the UCB cell dose. If this preliminary observation is correct, we may be able to improve the outcomes of haplo cord transplant further by accepting lower threshold UCB doses and rather focusing on optimal matching (including matching for HLA and another characteristic called IPA). This is the primary objective of this study.
Source references
references
  1. citation
    van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 Jun 25;3(12):1858-1867. doi: 10.1182/bloodadvances.2019000200.
    pmid
    31217161
    type
    DERIVED
  2. citation
    van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.
    pmid
    26869630
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-f29c864a6d1f0317a63c
      requested nct id
      NCT01810588
      primary nct id
      NCT01810588
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      576b1f86ac5f632b366115b407766fa5f676a8931d3647353dab74cbdc0aac75
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-f29c864a6d1f0317a63c
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01810588
      occurrences
      1. context exact
        NCT01810588
        end
        11
        exact text
        NCT01810588
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/204/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5c7994d92f29a1b7c75285f4c07013cb5898f39b8fe13645a93f8cf692ee64b3

    Preserved source evidence · Not medical advice